Literature DB >> 25189553

Congenital tuberculosis and management of exposure in neonatal and pediatric intensive care units.

G Grisaru-Soen1, M Savyon2, E Sadot3, V Schechner4, Y Sivan3, D Schwartz5, J Tarabeia4, Z Amitai2, I Yoabov2, Y Carmeli3.   

Abstract

SETTING: This report describes the management and outcome of neonatal intensive care unit (NICU) and paediatric ICU (PICU) exposure to a 26-day-old premature infant with congenital tuberculosis (TB).
DESIGN: The infant's mother underwent chest X-ray (CXR) and sputum culture. Contacts of the infant were identified. Tuberculin skin tests (TSTs) were performed on 97 infants and children, 156 NICU and PICU visitors and 115 health care workers.
RESULTS: The mother's sputum culture was positive for Mycobacterium tuberculosis. No TST conversion occurred in the exposed NICU infants. All neonates received prophylactic isoniazid (INH). One exposed child in the PICU had TST conversion with normal CXR and completed 9 months of INH without developing active disease; 22 (14%) PICU and NICU visitors and 3 NICU personnel had TST conversion without evidence of disease.
CONCLUSIONS: The sequence of events described here demonstrates the difficulty in diagnosis and management of TB in this age group. Transmission of TB in NICU and PICUs is unusual but can occur, and calls for a systematic approach to investigation of the exposed infants, family members and health care providers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25189553     DOI: 10.5588/ijtld.14.0160

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  1 in total

1.  Notes from the Field: Contact Investigation for an Infant with Congenital Tuberculosis Infection - North Carolina, 2016.

Authors:  Jessica L Rinsky; Darlene Farmer; Jessica Dixon; Jean-Marie Maillard; Thomas Young; Jason Stout; Amina Ahmed; Aaron Fleischauer; Jennifer MacFarquhar; Zack Moore
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-06-15       Impact factor: 17.586

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.